内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NKTR 内克塔治疗

交易中 12-23 13:34:40 EST

0.9113

-0.0170

-1.83%

最高0.9245	最低0.8701	成交量98.98万
今开0.9200	昨收0.9283	日振幅5.86%
总市值1.68亿	流通市值1.51亿	总股本1.84亿
成交额89.30万	换手率0.60%	流通股本1.66亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"内克塔治疗","latestPrice":0.9113,"timestamp":1734978870563,"preClose":0.9283,"halted":0,"volume":989760,"delay":0,"floatShares":165592296,"shares":184458284,"eps":-0.837394,"marketStatus":"交易中","marketStatusCode":2,"change":-0.017,"latestTime":"12-23 13:34:40 EST","open":0.92,"high":0.9245,"low":0.8701,"amount":892955.434464,"amplitude":0.058602,"askPrice":0.9145,"askSize":400,"bidPrice":0.9017,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.837394,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1734987600000},"adr":0,"adjPreClose":0.9283,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":0.977,"preClose":0.9283,"latestTime":"08:00 EST","volume":2125,"amount":2076.125,"timestamp":1734958801273},"postHourTrading":{"tag":"盘后","latestPrice":0.9865,"preClose":0.9283,"latestTime":"17:42 EST","volume":93019,"amount":86361.1291,"timestamp":1734734569101},"volumeRatio":1.025351,"impliedVol":0.6075,"impliedVolPercentile":0.1514},"requestUrl":"/m/hq/s/NKTR/tweets","defaultTab":"tweets","newsList":[{"id":"2493551761","title":"内克塔治疗盘中异动 股价大跌5.19%报0.880美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2493551761","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2493551761?lang=zh_cn&edition=full","pubTime":"2024-12-23 23:12","pubTimestamp":1734966728,"startTime":"0","endTime":"0","summary":"北京时间2024年12月23日23时12分，内克塔治疗股票出现波动，股价快速跳水5.19%。截至发稿，该股报0.880美元/股，成交量19.5947万股，换手率0.11%，振幅4.19%。机构评级方面，在所有8家参与评级的机构中，38%的券商给予买入建议，50%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.20%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223231208984d3c3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241223231208984d3c3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2492109974","title":"内克塔治疗盘中异动 急速上涨5.23%报0.974美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492109974","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492109974?lang=zh_cn&edition=full","pubTime":"2024-12-20 00:50","pubTimestamp":1734627017,"startTime":"0","endTime":"0","summary":"北京时间2024年12月20日00时50分，内克塔治疗股票出现异动，股价急速拉升5.23%。截至发稿，该股报0.974美元/股，成交量59.2135万股，换手率0.32%，振幅8.57%。机构评级方面，在所有8家参与评级的机构中，38%的券商给予买入建议，50%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为1.63%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220005018984cdb9f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241220005018984cdb9f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2492153700","title":"内克塔治疗盘中异动 股价大跌5.33%报0.966美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2492153700","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492153700?lang=zh_cn&edition=full","pubTime":"2024-12-19 03:55","pubTimestamp":1734551706,"startTime":"0","endTime":"0","summary":"北京时间2024年12月19日03时55分，内克塔治疗股票出现异动，股价急速下挫5.33%。截至发稿，该股报0.966美元/股，成交量79.4456万股，换手率0.43%，振幅6.85%。机构评级方面，在所有8家参与评级的机构中，38%的券商给予买入建议，50%的券商给予持有建议，12%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为1.91%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219035507984cb778&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219035507984cb778&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2489914160","title":"内克塔治疗盘中异动 股价大跌5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2489914160","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489914160?lang=zh_cn&edition=full","pubTime":"2024-12-05 04:04","pubTimestamp":1733342669,"startTime":"0","endTime":"0","summary":"北京时间2024年12月05日04时04分，内克塔治疗股票出现异动，股价急速下跌5.14%。截至发稿，该股报1.02美元/股，成交量495.134万股，换手率2.68%，振幅5.61%。机构评级方面，在所有7家参与评级的机构中，29%的券商给予买入建议，57%的券商给予持有建议，14%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.43%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205040429971bae3c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241205040429971bae3c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2488220670","title":"内克塔治疗盘中异动 股价大涨5.23%报1.20美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2488220670","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2488220670?lang=zh_cn&edition=full","pubTime":"2024-12-02 23:00","pubTimestamp":1733151617,"startTime":"0","endTime":"0","summary":"北京时间2024年12月02日23时00分，内克塔治疗股票出现波动，股价快速拉升5.23%。截至发稿，该股报1.20美元/股，成交量14.2953万股，换手率0.08%，振幅3.95%。机构评级方面，在所有7家参与评级的机构中，29%的券商给予买入建议，57%的券商给予持有建议，14%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.02%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120223001798e4ecc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024120223001798e4ecc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2486871590","title":"内克塔治疗盘中异动 早盘急速上涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486871590","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486871590?lang=zh_cn&edition=full","pubTime":"2024-11-28 00:08","pubTimestamp":1732723719,"startTime":"0","endTime":"0","summary":"北京时间2024年11月28日00时08分，内克塔治疗股票出现波动，股价急速拉升5.14%。截至发稿，该股报1.13美元/股，成交量39.9937万股，换手率0.22%，振幅3.74%。机构评级方面，在所有7家参与评级的机构中，29%的券商给予买入建议，57%的券商给予持有建议，14%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.43%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112800083998e44f95&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112800083998e44f95&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2486368890","title":"内克塔治疗盘中异动 早盘快速上涨5.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486368890","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486368890?lang=zh_cn&edition=full","pubTime":"2024-11-25 23:21","pubTimestamp":1732548079,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日23时21分，内克塔治疗股票出现异动，股价急速上涨5.24%。截至发稿，该股报1.11美元/股，成交量46.5422万股，换手率0.25%，振幅2.86%。机构评级方面，在所有7家参与评级的机构中，29%的券商给予买入建议，57%的券商给予持有建议，14%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为2.03%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112523211998e446f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112523211998e446f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2485261451","title":"内克塔治疗盘中异动 股价大涨5.45%报1.07美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2485261451","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485261451?lang=zh_cn&edition=full","pubTime":"2024-11-22 22:48","pubTimestamp":1732286937,"startTime":"0","endTime":"0","summary":"北京时间2024年11月22日22时48分，内克塔治疗股票出现异动，股价急速拉升5.45%。截至发稿，该股报1.07美元/股，成交量30.3846万股，换手率0.16%，振幅4.46%。机构评级方面，在所有7家参与评级的机构中，29%的券商给予买入建议，57%的券商给予持有建议，14%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.40%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122224857a24e28c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122224857a24e28c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2484104175","title":"内克塔治疗2024财年第三财季实现净利润-37.06百万美元，同比增加19.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484104175","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484104175?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:03","pubTimestamp":1731772995,"startTime":"0","endTime":"0","summary":"11月17日，内克塔治疗公布财报，公告显示公司2024财年第三财季净利润为-37.06百万美元，同比增加19.15%；其中营业收入为24.12百万美元，同比减少0.08%，每股基本收益为-0.18美元。从资产负债表来看，内克塔治疗总负债2.59亿美元，其中短期债务21.50百万美元，资产负债比为1.19，流动比率为0.05。机构评级：截至2024年11月17日，当前有4家机构对内克塔治疗目标价做出预测，其中目标均价为3.58美元，其中最低目标价为1.30美元，最高目标价为7.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000423abc790ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000423abc790ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR"],"gpt_icon":0},{"id":"2483964800","title":"内克塔治疗盘中异动 急速下挫5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483964800","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483964800?lang=zh_cn&edition=full","pubTime":"2024-11-14 23:20","pubTimestamp":1731597601,"startTime":"0","endTime":"0","summary":"北京时间2024年11月14日23时20分，内克塔治疗股票出现波动，股价急速下挫5.08%。截至发稿，该股报1.22美元/股，成交量27.9651万股，换手率0.15%，振幅6.25%。机构评级方面，在所有7家参与评级的机构中，29%的券商给予买入建议，57%的券商给予持有建议，14%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.88%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114232001abc17594&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114232001abc17594&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2483052688","title":"内克塔治疗盘中异动 临近收盘股价大跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483052688","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483052688?lang=zh_cn&edition=full","pubTime":"2024-11-13 04:53","pubTimestamp":1731444787,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日04时53分，内克塔治疗股票出现异动，股价大幅下跌5.11%。截至发稿，该股报1.30美元/股，成交量75.7911万股，换手率0.41%，振幅5.47%。机构评级方面，在所有7家参与评级的机构中，29%的券商给予买入建议，57%的券商给予持有建议，14%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为1.02%。内克塔治疗公司简介：Nektar Therapeutics 是一家制药公司，专注于发现和开发选择性调节免疫系统以治疗自身免疫性疾病的新疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113045307a231692d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113045307a231692d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2481192740","title":"Nektar Therapeutics 公布截至 9 月 30 日的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2481192740","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481192740?lang=zh_cn&edition=full","pubTime":"2024-11-08 12:39","pubTimestamp":1731040750,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics 公布截至 9 月 30 日的季度业绩 - 收益摘要Nektar Therapeutics NKTR.OQ报告，截至9月30日的季度调整后每股亏损18美分，高于去年同期的每股-24美分。七位分析师对该季度的平均预期是每股亏损 21 美分。Nektar Therapeutics 公布的本季度每股收益为亏损 18 美分。该公司当季亏损 3706 万美元。Nektar Therapeutics 的股价本季度上涨了 6.9%，今年迄今为止上涨了 146.0%。华尔街对 Nektar Therapeutics 12 个月目标价的中位数为 4.00 本摘要由 LSEG 11 月 8 日上午 04:38  的调制解调器器生成。如有任何其他问题或反馈，请联系 RefinitivNewsSupport@thomsonreuters.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL4T3MF0H3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2481685915","title":"内克塔治疗盘中异动 早盘股价大涨5.23%报1.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481685915","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481685915?lang=zh_cn&edition=full","pubTime":"2024-11-05 22:46","pubTimestamp":1730817995,"startTime":"0","endTime":"0","summary":"北京时间2024年11月05日22时46分，内克塔治疗股票出现异动，股价大幅上涨5.23%。截至发稿，该股报1.40美元/股，成交量18.2392万股，换手率0.10%，振幅4.51%。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.11%。内克塔治疗公司简介：Nektar Therapeutics是一家生物制药公司。在病毒学方面，该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105224635aba243f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241105224635aba243f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2480819885","title":"内克塔治疗盘中异动 早盘股价大涨14.23%报1.41美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2480819885","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480819885?lang=zh_cn&edition=full","pubTime":"2024-11-04 22:31","pubTimestamp":1730730686,"startTime":"0","endTime":"0","summary":"北京时间2024年11月04日22时31分，内克塔治疗股票出现波动，股价快速上涨14.23%。截至发稿，该股报1.41美元/股，成交量63.985万股，换手率0.35%，振幅6.50%。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.14%。内克塔治疗公司简介：Nektar Therapeutics是一家生物制药公司。在病毒学方面，该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110422312695bdc9a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110422312695bdc9a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2480818268","title":"Nektar Therapeutics    预计每股亏损 21 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2480818268","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480818268?lang=zh_cn&edition=full","pubTime":"2024-11-02 12:04","pubTimestamp":1730520288,"startTime":"0","endTime":"0","summary":"   * Nektar Therapeutics    将于11月7日公布截至2024年9月30日的财报，预计季度收入将出现下降。* 根据LSEG的数据，6位分析师的平均预期显示，这家总部位于加利福尼亚州旧金山的公司的营收将从去年同期的2414万美元下降24.3%，至1828.4万美元。* LSEG 分析师对 Nektar Therapeutics 的平均预期是每股亏损 21 美分。* 华尔街对 Nektar Therapeutics 的 12 个月目标价中位数为 2.65 美元，高于其上次收盘价 1.23 美元。11月2日 - 以往季度业绩。除非另有说明，否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","NKTR"],"gpt_icon":0},{"id":"2480922834","title":"内克塔治疗盘中异动 大幅上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480922834","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480922834?lang=zh_cn&edition=full","pubTime":"2024-11-02 00:41","pubTimestamp":1730479312,"startTime":"0","endTime":"0","summary":"北京时间2024年11月02日00时41分，内克塔治疗股票出现波动，股价快速拉升5.04%。截至发稿，该股报1.25美元/股，成交量29.1971万股，换手率0.16%，振幅2.69%。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.75%。内克塔治疗公司简介：Nektar Therapeutics是一家生物制药公司。该公司拥有肿瘤学、免疫学和病毒学研究药物的全资研发管线，以及一系列获批的合作药物。在病毒学方面，该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241102004152ab93b3d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241102004152ab93b3d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2479794434","title":"内克塔治疗盘中异动 大幅拉升5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479794434","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479794434?lang=zh_cn&edition=full","pubTime":"2024-10-29 00:49","pubTimestamp":1730134162,"startTime":"0","endTime":"0","summary":"北京时间2024年10月29日00时49分，内克塔治疗股票出现异动，股价快速拉升5.30%。截至发稿，该股报1.39美元/股，成交量36.309万股，换手率0.20%，振幅4.17%。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.24%。内克塔治疗公司简介：Nektar Therapeutics是一家生物制药公司。该公司拥有肿瘤学、免疫学和病毒学研究药物的全资研发管线，以及一系列获批的合作药物。在病毒学方面，该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029004923971a2b6c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241029004923971a2b6c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2476101975","title":"内克塔治疗盘中异动 急速拉升5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2476101975","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476101975?lang=zh_cn&edition=full","pubTime":"2024-10-18 00:12","pubTimestamp":1729181538,"startTime":"0","endTime":"0","summary":"北京时间2024年10月18日00时12分，内克塔治疗股票出现波动，股价大幅拉升5.07%。截至发稿，该股报1.45美元/股，成交量95.2936万股，换手率0.52%，振幅5.80%。内克塔治疗股票所在的生物技术行业中，整体涨幅为0.73%。内克塔治疗公司简介：Nektar Therapeutics是一家生物制药公司。在病毒学方面，该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018001218ab6ade21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018001218ab6ade21&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NKTR"],"gpt_icon":0},{"id":"2475197239","title":"内克塔治疗盘中异动 股价大涨5.43%报1.36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2475197239","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475197239?lang=zh_cn&edition=full","pubTime":"2024-10-16 22:47","pubTimestamp":1729090023,"startTime":"0","endTime":"0","summary":"北京时间2024年10月16日22时47分，内克塔治疗股票出现波动，股价大幅拉升5.43%。截至发稿，该股报1.36美元/股，成交量17.6407万股，换手率0.10%，振幅5.43%。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.40%。内克塔治疗公司简介：Nektar Therapeutics是一家生物制药公司。在病毒学方面，该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101622470398e3cce5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101622470398e3cce5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0},{"id":"2475398756","title":"内克塔治疗盘中异动 快速下挫5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2475398756","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2475398756?lang=zh_cn&edition=full","pubTime":"2024-10-14 22:12","pubTimestamp":1728915175,"startTime":"0","endTime":"0","summary":"北京时间2024年10月14日22时12分，内克塔治疗股票出现异动，股价快速下跌5.15%。机构评级方面，在所有6家参与评级的机构中，17%的券商给予买入建议，67%的券商给予持有建议，16%的券商给予卖出建议。内克塔治疗股票所在的生物技术行业中，整体跌幅为0.02%。内克塔治疗公司简介：Nektar Therapeutics是一家生物制药公司。在病毒学方面，该公司认为选择性免疫调节剂可用于解决人类的病毒感染问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101422125598e3c4ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024101422125598e3c4ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NKTR","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0809},{"period":"1month","weight":-0.0717},{"period":"3month","weight":-0.2859},{"period":"6month","weight":-0.1997},{"period":"1year","weight":0.9667},{"period":"ytd","weight":0.643}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nektar Therapeutics于1990年在加州成立，并于1998年重新在特拉华州注册。该公司是一家临床阶段、研究型药物发现生物制药公司，专注于发现和开发免疫治疗领域的创新药物。在这个不断增长的领域内，该公司致力于创造新的免疫调节剂，选择性地诱导、放大、减弱或阻止免疫反应，以达到预期的治疗效果。","yearOnYearQuotes":[{"month":1,"riseRate":0.566667,"avgChangeRate":0.047978},{"month":2,"riseRate":0.5,"avgChangeRate":0.00268},{"month":3,"riseRate":0.4,"avgChangeRate":0.004229},{"month":4,"riseRate":0.433333,"avgChangeRate":0.006304},{"month":5,"riseRate":0.366667,"avgChangeRate":0.006185},{"month":6,"riseRate":0.387097,"avgChangeRate":-0.018715},{"month":7,"riseRate":0.451613,"avgChangeRate":-0.014995},{"month":8,"riseRate":0.451613,"avgChangeRate":0.034164},{"month":9,"riseRate":0.483871,"avgChangeRate":0.014638},{"month":10,"riseRate":0.354839,"avgChangeRate":-0.028591},{"month":11,"riseRate":0.677419,"avgChangeRate":0.089799},{"month":12,"riseRate":0.612903,"avgChangeRate":0.027338}],"exchange":"NASDAQ","name":"内克塔治疗","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"内克塔治疗,NKTR,内克塔治疗股票,内克塔治疗股票老虎,内克塔治疗股票老虎国际,内克塔治疗行情,内克塔治疗股票行情,内克塔治疗股价,内克塔治疗股市,内克塔治疗股票价格,内克塔治疗股票交易,内克塔治疗股票购买,内克塔治疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"内克塔治疗(NKTR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供内克塔治疗(NKTR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}